When the alpha-synuclein protein is present at high concentrations around cellular membranes, it lifts up rather than lying flat against the membrane, making it more prone to clumping, a study shows. The finding may offer insight into the molecular mechanisms that drive Parkinson’s disease, where toxic clumps of alpha-synuclein…
Michael J. Fox has received the 2023 Elevate Prize Catalyst Award in recognition of his work with the Michael J. Fox Foundation for Parkinson’s Research (MJFF), an organization dedicated to developing better treatments, and eventually, finding a cure for the Parkinson’s disease. Granted by the Elevate Prize…
Dopamine-making neurons — whose loss characterizes Parkinson’s disease — produce thousands of circular RNA molecules that, beyond their normal duties, may play a role in neurodegenerative diseases, a study reports. “Circular RNA has long been cast aside as junk, but we believe it has an important role in programming…
Note: This story was updated Sept. 20, 2023, to reflect that Acadia is working on Nuplazid’s development as a treatment for schizophrenia. The U.S. Food and Drug Administration (FDA) has updated the prescribing label for Nuplazid (pimavanserin) — an approved therapy for Parkinson’s disease-related hallucinations and delusions…
The parkin enzyme — whose loss is a known genetic risk factor of Parkinson’s disease — not only helps to regulate healthy activity of energy-generating mitochondria, but also plays critical roles in nerve cell communication, according to a study using patient-derived neurons. Particularly, parkin loss resulted in defective recycling…
The Parkinson’s Foundation has launched a day of giving in an effort to encourage Parkinson’s disease awareness and raise funds to accelerate research and improve care for people living with the neurodegenerative disease. The inaugural event, called A Day to Reach Further, is today, Sept. 19. Lasting…
The 2024 Breakthrough Prize in Life Sciences has been awarded to three researchers who made groundbreaking discoveries related to the genetic causes of Parkinson’s disease. Breakthrough Prizes, popularly called the “Oscars of Science,” honor researchers who’ve made impactful discoveries across the life sciences, fundamental physics, and mathematics. There were…
A platform developed by NeuraLight that uses machine learning to measure eye movements may help track the progression of Parkinson’s disease, a study shows. “NeuraLight’s technology enables us to assess the patient’s neurological status in a sensitive and objective way. The results of this study mark an important…
Researchers have developed a new tool, called RETFound, to analyze images of the eyes using artificial intelligence (AI). The scientists showed this tool can be used to accurately identify eye diseases, and it could even identify other disorders including heart failure and Parkinson’s disease. “This is another big step…
An ethics committee in Australia has cleared Gain Therapeutics to start a Phase 1 clinical trial testing GT-02287, the company’s experimental oral therapy for Parkinson’s disease associated with mutations in the GBA1 gene. GT-02287 now will become the first treatment candidate discovered with Gain’s proprietary platform, SEE-Tx, to…
Get regular updates to your inbox.
